DUALITYBIO-B(09606),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09606 DUALITYBIO-B

Market Closed 04-10 16:09:20

303.000

-0.200

-0.07%

High312.000	Low298.200	Vol767.01K
Open308.400	D1 Closing303.200	Amplitude4.55%
Mkt Cap27.34B	Tradable Cap27.34B	Total Shares90.24M
T/O232.09M	T/O Rate0.85%	Tradable Shares90.24M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"DUALITYBIO-B","latestPrice":303,"timestamp":1775808560010,"preClose":303.2,"halted":0,"volume":767009,"delay":0,"changeRate":-0.0006596306068601209,"floatShares":90238000,"shares":90238000,"eps":-45.615297379427005,"marketStatus":"Market Closed","change":-0.2,"latestTime":"04-10 16:09:20","open":308.4,"high":312,"low":298.2,"amount":232089506,"amplitude":0.045515,"askPrice":303.2,"askSize":2100,"bidPrice":303,"bidSize":3900,"shortable":3,"etf":0,"ttmEps":-36.52891351952507,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":7,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":303.2,"openAndCloseTimeList":[[1775784600000,1775793600000],[1775797200000,1775808000000]],"volumeRatio":0.4442833510066221,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09606/tweets","defaultTab":"tweets","newsList":[{"id":"2626219475","title":"DualityBio says China NMPA accepts trastuzumab pamirtecan breast cancer BLA for review","url":"https://stock-news.laohu8.com/highlight/detail?id=2626219475","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626219475?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:24","pubTimestamp":1775820278,"startTime":"0","endTime":"0","summary":"DualityBio said China NMPA accepted for review its BLA for trastuzumab pamirtecan  in HER2-positive unresectable or metastatic breast cancer.Filing seeks approval as second-line therapy versus Roche’s Kadcyla , based on interim Phase III data showing a statistically significant progression-free survival benefit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire  on April 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL9PtyL1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2543165471.USD","HK0000500386.USD","HK0000252152.HKD","BK1161","09606","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626812591","title":"Dualitybio Announces China Nmpa Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic Her2-Positive Adult Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626812591","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626812591?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:56","pubTimestamp":1775735770,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nTUA9T0R2M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2543165471.USD","09606","HK0000252152.HKD","HK0000252160.HKD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150883471","title":"DUALITYBIO-B's New Drug Application for HER2-Positive Breast Cancer Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1150883471","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150883471?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:54","pubTimestamp":1775732071,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) has announced that its Biologics License Application (BLA) for DB-1303/BNT323 has been accepted by the National Medical Products Administration (NMPA). This submission is based...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4118","LU2543165471.USD","BK4585","BK4588","DB","HK0000500386.USD","BK1161","IPOS","BK4552","HK0000252160.HKD","BK4566","HK0000252152.HKD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626186811","title":"BRIEF-Duality Biotherapeutics Says NMPA Accepts Biologics License Application For Db-1303/Bnt323","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186811","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186811?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:53","pubTimestamp":1775731991,"startTime":"0","endTime":"0","summary":"BRIEF-Duality Biotherapeutics Says NMPA Accepts Biologics License Application For Db-1303/Bnt323April 9  - Duality Biotherapeutics Inc 9606.HK:NMPA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR DB-1303/BNT323 IN HER2-POSITIVE BREAST CANCERFurther company coverage: 9606.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","HK0000252152.HKD","HK0000252160.HKD","LU2543165471.USD","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626518507","title":"Duality Biotherapeutics Inc - Nmpa Accepts Biologics License Application for Db-1303/Bnt323 in Her2-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626518507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626518507?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:49","pubTimestamp":1775731759,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252152.HKD","LU2543165471.USD","BK1161","HK0000500386.USD","09606","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626185005","title":"Duality Biotherapeutics says China NMPA accepts BLA for DB-1303 in HER2+ breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2626185005","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626185005?lang=en_us&edition=fundamental","pubTime":"2026-04-09 18:49","pubTimestamp":1775731759,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics secured NMPA acceptance of biologics license application for DB-1303/BNT323 in unresectable or metastatic HER2-positive breast cancer in adults.Filing was supported by Phase III DB-1303-O-3001 data showing statistically significant progression-free survival improvement versus Roche’s Kadcyla .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL7bhTxC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252160.HKD","09606","LU2543165471.USD","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172387094","title":"Duality Biotherapeutics Sets 24–29 April 2026 Book Closure for Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1172387094","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172387094?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:41","pubTimestamp":1775724115,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. will convene an Extraordinary General Meeting (EGM) at 9:00 a.m. on Wednesday, 29 April 2026, in the Board Room, 11/F, Building A, No. 868 Yinghua Road, Pudong New Area,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626027389","title":"Duality Biotherapeutics announces extraordinary general meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626027389","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626027389?lang=en_us&edition=fundamental","pubTime":"2026-04-09 16:38","pubTimestamp":1775723893,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics scheduled an extraordinary general meeting in Shanghai on April 29, 2026.Share register closure set for April 24–29, 2026 to determine shareholder eligibility for the meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Duality Biotherapeutics Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL2Cgwcs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","LU2543165471.USD","BK1161","HK0000500386.USD","09606","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149528263","title":"HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149528263","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149528263?lang=en_us&edition=fundamental","pubTime":"2026-03-27 14:14","pubTimestamp":1774592089,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio up 7%; Hengrui Pharma and Junshi Bio Up 6%; HBM, Beigene, $Sihuan Pharm(00460)$ Up 5%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"69cd48097efa50f044ce5ac6380125f5","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02269","09995","03347","01672","06978","06606","09688","01276","02137","02157","02359","09606","02268","09966","01093","03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139469969","title":"DualityBio-B Maintains Outperform Rating with HK$430 Target from CICC","url":"https://stock-news.laohu8.com/highlight/detail?id=1139469969","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139469969?lang=en_us&edition=fundamental","pubTime":"2026-03-27 10:36","pubTimestamp":1774578988,"startTime":"0","endTime":"0","summary":"CICC has reiterated its Outperform rating on DUALITYBIO-B (09606) with an unchanged target price of HK$430, implying a 63.4% upside potential from the current share price, based on a DCF valuation...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","BK1161","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178986582","title":"Stock Track | Duality Biotherapeutics Soars 5% Intraday as Analysts Boost Estimates After Earnings Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1178986582","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178986582?lang=en_us&edition=fundamental","pubTime":"2026-03-27 10:17","pubTimestamp":1774577840,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics (HKG:09606) saw its stock price soar 5.00% during intraday trading on Friday, following the release of its annual results and subsequent analyst updates.The biotech company's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622135258","title":"Earnings Update: Duality Biotherapeutics, Inc. (HKG:9606) Just Reported And Analysts Are Boosting Their Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2622135258","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622135258?lang=en_us&edition=fundamental","pubTime":"2026-03-27 06:05","pubTimestamp":1774562708,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics, Inc. ( HKG:9606 ) shareholders are probably feeling a little disappointed, since its shares...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9606/duality-biotherapeutics-shares/news/earnings-update-duality-biotherapeutics-inc-hkg9606-just-rep","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9606/duality-biotherapeutics-shares/news/earnings-update-duality-biotherapeutics-inc-hkg9606-just-rep","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148472362","title":"HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.","url":"https://stock-news.laohu8.com/highlight/detail?id=1148472362","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148472362?lang=en_us&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490045,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. XuanzhuBio up 9%; Xtalpi, Lepu Bio and Ascletis up 6%; Akeso up 5%; Skb Bio up 4%. ","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"b776b6268e0a69a5ca2da5ea0fb0b0d4","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672","06606","09606","03759","02268","02269","09688","02228","06978","09966","02359","03347","09995","02157","02137","02575"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621548880","title":"Dualitybio (9606.HK) Announces 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621548880","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621548880?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:43","pubTimestamp":1774338231,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nTUA5JTWZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09606","HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621054815","title":"Press Release: DualityBio (9606.HK) Announces 2025 Annual Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2621054815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621054815?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:43","pubTimestamp":1774338180,"startTime":"0","endTime":"0","summary":"HONG KONG, March 24, 2026 /PRNewswire/ -- Duality Biotherapeutics, Inc. , a leading global clinical-stage innovative biopharmaceutical company, today announced its first annual results since listing on April 15, 2025 , providing a comprehensive update on its global clinical pipeline and corporate operations.During the reporting period, the Company achieved total revenue of RMB1.852 billion , providing a solid financial foundation for the continuous advancement of business. R&D investment remained at a high level, with annual R&D expenses reaching RMB838 million; the adjusted loss for the year was RMB389 million . The Company maintained a healthy cash flow position, with cash and bank balances of RMB3.325 billion as of the end o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4552","BK4118","DB","HK0000252160.HKD","BK4588","HK0000500386.USD","09606","LU2543165471.USD","HK0000252152.HKD","BK1161","BK4566","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148394372","title":"Stock Track | Duality Biotherapeutics Plummets 5.04% Intraday on Widened 2025 Loss and Revenue Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=1148394372","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148394372?lang=en_us&edition=fundamental","pubTime":"2026-03-24 11:09","pubTimestamp":1774321752,"startTime":"0","endTime":"0","summary":"Duality Biotherapeutics (09606.HK) shares plummeted 5.04% during intraday trading on Tuesday, following the release of its full-year 2025 financial results.The biopharmaceutical company reported a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156264604","title":"HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156264604","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156264604?lang=en_us&edition=fundamental","pubTime":"2026-03-24 09:46","pubTimestamp":1774316807,"startTime":"0","endTime":"0","summary":"HK Pharma Stocks Gained. Wuxi XDC up 8%; Wuxi AppTec up 7%; Transthera and HBM up 5%; Keymed Bio and Innocare up 4%; Wuxi Bio and Remegen up 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f33735d7734fa14183d39ed89303d740","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06606","09995","03347","09606","02268","03759","02162","06978","09966","02137","02359","09688","01672","02269"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621707467","title":"BRIEF-Duality Biotherapeutics FY Revenue Rmb1.85 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2621707467","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621707467?lang=en_us&edition=fundamental","pubTime":"2026-03-23 23:31","pubTimestamp":1774279896,"startTime":"0","endTime":"0","summary":"BRIEF-Duality Biotherapeutics FY Revenue Rmb1.85 BillionMarch 23 (Reuters) - Duality Biotherapeutics Inc 9606.HK:FY  REVENUE RMB1.85 BILLIONLOSS FOR YEAR ATTRIBUTABLE RMB2.59 BILLIONFurther company coverage: 9606.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B09R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","HK0000252152.HKD","HK0000252160.HKD","HK0000500386.USD","BK1161","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621570110","title":"BRIEF-Duality Biotherapeutics Inc Says Si Wen Tendered Resignation As Exec Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2621570110","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621570110?lang=en_us&edition=fundamental","pubTime":"2026-03-23 22:01","pubTimestamp":1774274511,"startTime":"0","endTime":"0","summary":"BRIEF-Duality Biotherapeutics Inc Says Si Wen Tendered Resignation As Exec DirectorMarch 23  - Duality Biotherapeutics 9606.HK:SI WEN TENDERED HER RESIGNATION AS AN EXECUTIVE DIRECTORHUA HAIQING HAS BEEN APPOINTED AS AN EXECUTIVE DIRECTORZHANG SHAOREN HAS BEEN APPOINTED AS CFOFurther company coverage: 9606.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nFWN40B0S6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","LU2543165471.USD","HK0000252152.HKD","09606","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141225275","title":"DUALITYBIO-B Reports 2025 Revenue of Approximately 18.52 Billion Yuan, Marking Significant Pipeline and Operational Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1141225275","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141225275?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:58","pubTimestamp":1774270703,"startTime":"0","endTime":"0","summary":"DUALITYBIO-B (09606) announced its 2025 financial results, achieving revenue of approximately 18.52 billion yuan and a gross profit of about 5.89 billion yuan. Research and development expenses were...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606","HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD","BK1161","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dualitybiologics.com","stockEarnings":[{"period":"1week","weight":-0.0637},{"period":"1month","weight":-0.0026},{"period":"3month","weight":-0.1607},{"period":"6month","weight":0.0278},{"period":"1year","weight":2.203},{"period":"ytd","weight":0.0161}],"compareEarnings":[{"period":"1week","weight":0.0309},{"period":"1month","weight":-0.0002},{"period":"3month","weight":-0.0129},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.252},{"period":"ytd","weight":0.0103}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets.","exchange":"SEHK","name":"DUALITYBIO-B","nameEN":"DUALITYBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"DUALITYBIO-B(09606),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest DUALITYBIO-B(09606) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"DUALITYBIO-B,09606,DUALITYBIO-B股票,DUALITYBIO-B股票老虎,DUALITYBIO-B股票老虎国际,DUALITYBIO-B行情,DUALITYBIO-B股票行情,DUALITYBIO-B股价,DUALITYBIO-B股市,DUALITYBIO-B股票价格,DUALITYBIO-B股票交易,DUALITYBIO-B股票购买,DUALITYBIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"DUALITYBIO-B(09606),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest DUALITYBIO-B(09606) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}